1. Home
  2. NP vs CRSP Comparison

NP vs CRSP Comparison

Compare NP & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neptune Insurance Holdings Inc.

NP

Neptune Insurance Holdings Inc.

HOLD

Current Price

$31.48

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$48.25

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NP
CRSP
Founded
2017
2013
Country
United States
Switzerland
Employees
60
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.0B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NP
CRSP
Price
$31.48
$48.25
Analyst Decision
Buy
Buy
Analyst Count
12
17
Target Price
$28.17
$70.29
AVG Volume (30 Days)
936.6K
1.6M
Earning Date
04-22-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
$25.84
$807.72
Revenue Next Year
$15.80
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$14.78
$44.12
52 Week High
$34.61
$78.48

Technical Indicators

Market Signals
Indicator
NP
CRSP
Relative Strength Index (RSI) 54.42 37.70
Support Level $23.62 $47.48
Resistance Level $31.63 $59.61
Average True Range (ATR) 1.53 3.29
MACD -0.24 -1.11
Stochastic Oscillator 40.72 7.76

Price Performance

Historical Comparison
NP
CRSP

About NP Neptune Insurance Holdings Inc.

Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: